Promising cervical cancer study: Combining drugs, chemo to extend life
Sunday, February 23, 2014 - 06:31
in Health & Medicine
New research has revealed that women with advanced cervical cancer live about four months longer with the combined use of bevacizumab (Avastin®) and chemotherapy compared to chemotherapy alone. Women who combined bevacizumab with chemotherapy lived an average of 17 months after diagnosis, while those who received chemotherapy alone lived 13.3 months. The multi-site research project is expected to change the standard of care in advanced cervical cancer.